A narrative review in Annals of Clinical and Translational Neurology calls early MS data reassuring, but says the drugs' value for treating the disease itself is still unproven.
Recap by typeshit. Full story at Bioengineer.org.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
An investing take on Novo Nordisk shares after a 75% drop, weighing whether the Wegovy maker is a bargain or a trap.
A clinical primer on the GIP/GLP-1 drug covering its use for blood sugar control and lowering the risk of adverse outcomes.
Loading…